What were the key findings of the AISA-021 Phase II trial?

The trial showed AISA-021 significantly increased attack-free days, improved attack duration and skin temperature, and offered benefits in pain and other symptoms.

Is AISA-021 safe for patients?

Yes, the drug was generally well-tolerated in the Phase II trial, with no treatment-related serious adverse events reported.

Home / Health / New Drug Shows Promise for Scleroderma Patients

New Drug Shows Promise for Scleroderma Patients

Q: What is AISA-021 and what condition does it treat?

AISA-021 is a drug candidate being tested for systemic sclerosis-associated Raynaud's phenomenon (SSc RP), a condition causing burdensome symptoms.

9 Mar

•

Summary

AISA-021 significantly increased attack-free days for Raynaud's patients.
The drug improved duration, skin temperature, and other symptoms.
No serious drug-related side effects were reported in the trial.

New Drug Shows Promise for Scleroderma Patients

Aisa Pharma has announced encouraging Phase II trial results for its drug candidate, AISA-021, targeting systemic sclerosis-associated Raynaud's phenomenon (SSc RP). The RECONNOITER trial demonstrated AISA-021's potential to alleviate burdensome symptoms associated with the condition.

During the trial, AISA-021 treatment led to a notable increase in attack-free days, a substantial improvement in attack duration, and enhanced skin temperature. Patients also reported benefits in pain and other non-Raynaud's symptoms.

The drug was generally well-tolerated, with no serious adverse events linked to the treatment reported. These outcomes pave the way for Aisa Pharma to engage with regulatory bodies like the FDA regarding future Phase III trials.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.